Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Gail J RobozKaren YeeAmit VermaGautam BorthakurAdolfo de la Fuente BurgueraGuillermo SanzHelai P MohammadRyan G KrugerNatalie O KarpinichGeraldine Ferron-BradyAndre AcustaHeather Del BuonoTherese CollingwoodMarc BallasArindam DharAndrew H Wei

Published in: Leukemia & lymphoma (2021)

Keyphrases

combination therapy
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
signaling pathway
acute lymphoblastic leukemia
amino acid
diffuse large b cell lymphoma
multiple myeloma
hodgkin lymphoma